DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.09
+0.08 (+7.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.01
Open1.00
Bid1.00 x 11000
Ask1.10 x 1400
Day's Range0.99 - 1.10
52 Week Range0.74 - 2.17
Volume861,777
Avg. Volume805,279
Market Cap161.92M
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateOct 30, 2017 - Nov 3, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.97
Trade prices are not sourced from all markets
  • Capital Cube12 hours ago

    ETFs with exposure to DURECT Corp. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire6 days ago

    Streetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double'

    SAN FRANCISCO, Nov. 15, 2017-- Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17.. Included in this article is: DURECT Corp.. A Nov. ...

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube12 days ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Heron Therapeutics Inc and Pacira Pharmaceuticals, Inc. (PTIE-US, ZGNX-US, JNJ-US, PFE-US, LLY-US, ... Read more (Read more...)

  • Capital Cube12 days ago

    ETFs with exposure to DURECT Corp. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT

    Q3 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research18 days ago

    DRRX: Focus will be Shifted to DUR-928 Programs

    Revenue from R&D collaborations was $5.6 million in third quarter 2017, compared to $0.4 million in third quarter 2016. A large portion of that increase related to the recognition of deferred revenue from upfront fees already received by the company.

  • Associated Press19 days ago

    Durect tops Street 3Q forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 4 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswire25 days ago

    DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif. , Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call ...

  • Capital Cube26 days ago

    ETFs with exposure to DURECT Corp. : October 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswirelast month

    DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint

    CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.  While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance.  POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.

  • Capital Cubelast month

    ETFs with exposure to DURECT Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Marketwired2 months ago

    Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia

    A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube2 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 4.32 million, Net Earnings of USD -9.93 million. Gross margins widened from 71.08% to 78.61% compared to the same period last year, operating (EBITDA) margins now -214.24% from -265.79%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC

    Pursuant to the agreement, DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • PR Newswire2 months ago

    DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement

    CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (INDV.L), whereby DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior today announced that it has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • PR Newswire2 months ago

    DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development

    CUPERTINO, Calif. , Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes ...

  • PR Newswire2 months ago

    DURECT to Participate in Upcoming Healthcare Conferences

    James E. Brown, President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday, September 12 at 12:30 p.m. Eastern time. The conference is being held at the Lotte New York Palace Hotel in New York City.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research3 months ago

    DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States

    On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.

  • Associated Press3 months ago

    Durect reports 2Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • PR Newswire3 months ago

    DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended ...

  • PR Newswire3 months ago

    ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan

    CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/-- DURECT Corporation (DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that a Phase 3 clinical study of ORADUR-Methylphenidate ER Capsule conducted in Taiwan has achieved positive results.  ORADUR-Methylphenidate ER Capsule is an investigational drug candidate for the treatment of attention deficit hyperactivity disorder (ADHD).

  • PR Newswire4 months ago

    DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif. , Aug. 1, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call ...

  • Capital Cube4 months ago

    ETFs with exposure to DURECT Corp. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Marketwired5 months ago

    Streetwise Reports Examines How Analysts Take Note as a Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial

    With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated ...